Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | +14.31% | +20.42% | +4.67% |
05-13 | Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures | MT |
05-13 | MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 149.4 | 88.18 | 36.94 | 34 | - | - |
Enterprise Value (EV) 1 | 149.4 | 88.18 | 36.94 | 34 | 34 | 34 |
P/E ratio | - | -3.14 x | -1.65 x | -1.9 x | -1.48 x | -1.44 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 8.25 x |
EV / Revenue | - | - | - | - | - | 8.25 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -11.4 x | - | - | -1.36 x | -0.75 x | -0.67 x |
FCF Yield | -8.75% | - | - | -73.5% | -133% | -150% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 33,504 | 33,786 | 34,520 | 34,704 | - | - |
Reference price 2 | 4.460 | 2.610 | 1.070 | 0.9798 | 0.9798 | 0.9798 |
Announcement Date | 18/03/22 | 21/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 4.124 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -28.36 | -30.95 | -22.92 | -22.02 | -31.96 | -39.85 |
Operating Margin | - | - | - | - | - | - | -966.28% |
Earnings before Tax (EBT) 1 | - | - | - | -22.46 | -19.06 | -28.18 | -28.53 |
Net income 1 | -16.24 | - | -27.99 | -22.46 | -19.06 | -36.39 | -40.23 |
Net margin | - | - | - | - | - | - | -975.5% |
EPS 2 | -1.870 | - | -0.8300 | -0.6500 | -0.5150 | -0.6633 | -0.6800 |
Free Cash Flow 1 | - | -13.08 | - | - | -25 | -45.24 | -50.9 |
FCF margin | - | - | - | - | - | - | -1,234.35% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 14/09/21 | 18/03/22 | 21/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -13.38 | -6.362 | -7.374 | -7.698 | -7.987 | -7.889 | -5.854 | -6.343 | -5.223 | -5.5 | -3.83 | -5.075 | -5.593 | -5.947 | -6.771 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | - | - | - | -5.686 | -6.197 | -5.116 | -5.459 | -3.813 | -4.271 | -4.748 | -4.979 | -6.73 |
Net income 1 | - | - | - | - | - | -7.769 | -5.686 | -6.197 | -5.116 | -5.459 | -3.813 | -4.271 | -4.748 | -4.979 | -6.797 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | - | - | - | - | - | -0.2300 | -0.1700 | -0.1800 | -0.1500 | -0.1500 | -0.1100 | -0.1200 | -0.1300 | -0.1300 | -0.1400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 29/11/21 | 18/03/22 | 13/05/22 | 09/08/22 | 03/11/22 | 21/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | 14/05/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -13.1 | - | - | -25 | -45.2 | -50.9 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.25 | - | - | - | 1 | 1.06 |
Capex / Sales | - | - | - | - | - | - | 25.75% |
Announcement Date | 14/09/21 | 18/03/22 | 21/03/23 | 21/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.67% | 34M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- INKT Stock
- Financials MiNK Therapeutics, Inc.